← ArriVent BioPharma, Inc. (AVBP) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
ArriVent BioPharma, Inc. (AVBP)
Pharmaceutical Preparations · market cap $1.5B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
ArriVent BioPharma (AVBP) is a clinical-stage pharma company with 52 employees and a ~$1.55B market cap built almost entirely on furmonertinib, an oral daily EGFR inhibitor in Phase 3 for metastatic non-small cell lung cancer. The company has $62.1M in cash — roughly 4.4 months of runway — against an annual R&D burn rate of ~$153M, making near-term financing an operational necessity rather than a possibility.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| furmonertinib 240 mg oral, daily | Phase 3 | Metastatic Non-Small Cell Lung Cancer |
| Firmonertinib | Phase 3 | Non-Small-Cell Lung Cancer |
Price & technical context
3-month
-16.6%
6-month
+19.4%
12-month
+56.8%
52-wk range
$17.60–$34.74
vs 50-day MA
-3.5%
vs 200-day MA
+6.0%
Realized vol
56.8%
Max drawdown
-54.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AVBP (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.